{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:21:17Z","timestamp":1793146877268,"version":"4.5.0"},"reference-count":59,"publisher":"European Respiratory Society (ERS)","issue":"1","funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI111965"],"award-info":[{"award-number":["R01 AI111965"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005430","name":"American Society for Microbiology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005430","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2018,1,29]]},"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>Ivacaftor\u2013lumacaftor and ivacaftor are two new breakthrough cystic fibrosis transmembrane conductance modulators.<\/jats:p><jats:p>The interactions of ivacaftor and its two metabolites hydroxymethylivacaftor (iva-M1) and ivacaftorcarboxylate (iva-M6) with neurotransmitter receptors were investigated in radioligand binding assays.<\/jats:p><jats:p>Ivacaftor displayed significant affinity to the 5-hydroxytryptamine (5-HT; serotonin) 5-HT<jats:sub>2C<\/jats:sub>receptor (p<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>=6.06\u00b10.03), \u03b2<jats:sub>3<\/jats:sub>-adrenergic receptor (p<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>=5.71\u00b10.07), \u03b4-opioid receptor (p<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>=5.59\u00b10.06) and the dopamine transporter (p<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>=5.50\u00b10.20); iva-M1 displayed significant affinity to the 5-HT<jats:sub>2C<\/jats:sub>receptor (p<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>=5.81\u00b10.04) and the muscarinic M3 receptor (p<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>=5.70\u00b10.10); iva-M6 displayed significant affinity to the 5-HT<jats:sub>2A<\/jats:sub>receptor (p<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>=7.33\u00b10.05). The<jats:italic>in vivo<\/jats:italic>central nervous system activity of ivacaftor (40\u2005mg\u00b7kg<jats:sup>\u22121<\/jats:sup>intraperitoneally for 21\u2005days) was assessed in a chronic mouse model of depression. In the forced swim test, the ivacaftor-treated group displayed decreased immobility (52.8\u00b17.6\u2005s), similarly to fluoxetine (33.8\u00b111.0\u2005s), and increased climbing\/swimming activity (181.5\u00b19.2\u2005s). In the open field test, ivacaftor produced higher locomotor activity than the fluoxetine group, measured both as mean number of paw touches (ivacaftor 81.1\u00b19.6<jats:italic>versus<\/jats:italic>fluoxetine 57.9\u00b19.5) and total distance travelled (ivacaftor 120.6\u00b116.8\u2005cm<jats:italic>versus<\/jats:italic>fluoxetine 84.5\u00b116.0\u2005cm) in 600\u2005s. Treatment of 23 cystic fibrosis patients with ivacaftor\u2013lumacaftor resulted in significant improvements in quality of life (including anxiety) in all five domains of the AweScoreCF questionnaire (p=0.092\u20130.096).<\/jats:p><jats:p>Our findings suggest ivacaftor displays potential clinical anxiolytic and stimulating properties, and may have beneficial effects on mood.<\/jats:p>","DOI":"10.1183\/23120541.00127-2017","type":"journal-article","created":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T00:10:23Z","timestamp":1520986223000},"page":"00127-2017","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["The potentially beneficial central nervous system activity profile of ivacaftor and its metabolites"],"prefix":"10.1183","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6044-4824","authenticated-orcid":false,"given":"Elena K.","family":"Schneider","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo C.","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felisa","family":"Reyes-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Button","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayame","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Velkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"2024101707054353000_4.1.00127-2017.1","doi-asserted-by":"publisher","DOI":"10.1002\/jmr.2447"},{"key":"2024101707054353000_4.1.00127-2017.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12567-6"},{"key":"2024101707054353000_4.1.00127-2017.3","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.1.29"},{"key":"2024101707054353000_4.1.00127-2017.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"2024101707054353000_4.1.00127-2017.5","doi-asserted-by":"publisher","DOI":"10.1080\/23808993.2016.1175299"},{"key":"2024101707054353000_4.1.00127-2017.6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904709106"},{"key":"2024101707054353000_4.1.00127-2017.7","unstructured":"Center for Drug Evaluation and Research. Sponsor briefing document: ORKAMBI (lumacaftor\/ivacaftor). Treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene. Vertex Pharmaceuticals. 2015. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2015\/0206038Orig1s000PharmR.pdf Date last accessed: February 22, 2018."},{"key":"2024101707054353000_4.1.00127-2017.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.10.001"},{"key":"2024101707054353000_4.1.00127-2017.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409547"},{"key":"2024101707054353000_4.1.00127-2017.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.02.004"},{"key":"2024101707054353000_4.1.00127-2017.11","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.6b00035"},{"key":"2024101707054353000_4.1.00127-2017.12","doi-asserted-by":"crossref","first-page":"e86183","DOI":"10.1172\/jci.insight.86183","article-title":"Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalities","volume":"1","author":"Adam","year":"2016","journal-title":"JCI Insight"},{"key":"2024101707054353000_4.1.00127-2017.13","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.051797"},{"key":"2024101707054353000_4.1.00127-2017.14","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145710001045"},{"key":"2024101707054353000_4.1.00127-2017.15","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0022-3565(24)39013-5","article-title":"Antidepressant-like behavioral effects mediated by 5-hydroxytryptamine2C receptors","volume":"295","author":"Cryan","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"2024101707054353000_4.1.00127-2017.16","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.133348"},{"key":"2024101707054353000_4.1.00127-2017.17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/oby.2008.537","article-title":"Lorcaserin (APD356), a selective 5-HT2C agonist, reduces body weight in obese men and women","volume":"17","author":"Smith","year":"2009","journal-title":"Obesity"},{"key":"2024101707054353000_4.1.00127-2017.18","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21238"},{"key":"2024101707054353000_4.1.00127-2017.19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jpsychires.2014.02.012","article-title":"A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia","volume":"53","author":"Shen","year":"2014","journal-title":"J Psychiatr Res"},{"key":"2024101707054353000_4.1.00127-2017.20","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s00213-017-4545-5","article-title":"A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment","volume":"234","author":"Palacios","year":"2017","journal-title":"Psychopharmacology"},{"key":"2024101707054353000_4.1.00127-2017.21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0031-6997(25)06783-3","article-title":"International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)","volume":"46","author":"Hoyer","year":"1994","journal-title":"Pharmacol Rev"},{"key":"2024101707054353000_4.1.00127-2017.22","doi-asserted-by":"publisher","DOI":"10.1038\/374542a0"},{"key":"2024101707054353000_4.1.00127-2017.23","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.51"},{"key":"2024101707054353000_4.1.00127-2017.24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-183X.2007.00316.x"},{"key":"2024101707054353000_4.1.00127-2017.25","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2584-06.2007"},{"key":"2024101707054353000_4.1.00127-2017.26","doi-asserted-by":"crossref","first-page":"RC71","DOI":"10.1523\/JNEUROSCI.20-08-j0003.2000","article-title":"A paradoxical locomotor response in serotonin 5-HT2C receptor mutant mice","volume":"20","author":"Heisler","year":"2000","journal-title":"J Neurosci"},{"key":"2024101707054353000_4.1.00127-2017.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1962-z"},{"key":"2024101707054353000_4.1.00127-2017.28","doi-asserted-by":"publisher","DOI":"10.2515\/therapie:2005065"},{"key":"2024101707054353000_4.1.00127-2017.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2009.09.011"},{"key":"2024101707054353000_4.1.00127-2017.30","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3829-2"},{"key":"2024101707054353000_4.1.00127-2017.31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00213-015-4112-x","article-title":"The 5-HT2C receptor agonist, lorcaserin, and the 5-HT6 receptor antagonist, SB-742457, promote satiety; a microstructural analysis of feeding behaviour","volume":"233","author":"Higgs","year":"2016","journal-title":"Psychopharmacology"},{"key":"2024101707054353000_4.1.00127-2017.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.09.028"},{"key":"2024101707054353000_4.1.00127-2017.33","doi-asserted-by":"publisher","DOI":"10.1002\/hup.868"},{"key":"2024101707054353000_4.1.00127-2017.34","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-200504000-00002"},{"key":"2024101707054353000_4.1.00127-2017.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2014.03.001"},{"key":"2024101707054353000_4.1.00127-2017.36","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2396(200001)35:1<53::AID-SYN7>3.0.CO;2-2"},{"key":"2024101707054353000_4.1.00127-2017.37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/adb.12137","article-title":"Serotonin2C receptors modulate dopamine transmission in the nucleus accumbens independently of dopamine release: behavioral, neurochemical and molecular studies with cocaine","volume":"20","author":"Cathala","year":"2015","journal-title":"Addict Biol"},{"key":"2024101707054353000_4.1.00127-2017.38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300433"},{"key":"2024101707054353000_4.1.00127-2017.39","unstructured":"Roth BL . National Institute of Mental Health Psychoactive Drug Screening Program Assay Protocol Book Version II. Chapel Hill, University of North Carolina, 2013."},{"key":"2024101707054353000_4.1.00127-2017.40","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch Int Pharmacodyn Ther"},{"key":"2024101707054353000_4.1.00127-2017.41","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1569-1993(15)30056-4","article-title":"Effect of ivacaftor on wellness, quality of life and cognitive function in adults with cystic fibrosis and G551D mutation","volume":"14","author":"Button","year":"2015","journal-title":"J Cystic Fibros"},{"key":"2024101707054353000_4.1.00127-2017.42","doi-asserted-by":"publisher","DOI":"10.1038\/266730a0"},{"key":"2024101707054353000_4.1.00127-2017.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-6147(02)02017-5"},{"key":"2024101707054353000_4.1.00127-2017.44","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.19-21-09550.1999"},{"key":"2024101707054353000_4.1.00127-2017.45","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(03)01272-X"},{"key":"2024101707054353000_4.1.00127-2017.46","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(94)90311-5"},{"key":"2024101707054353000_4.1.00127-2017.47","doi-asserted-by":"crossref","first-page":"246ra296","DOI":"10.1126\/scitranslmed.3008680","article-title":"Potentiator ivacaftor abrogates pharmacological correction of \u0394F508 CFTR in cystic fibrosis","volume":"6","author":"Cholon","year":"2014","journal-title":"Sci Transl Med"},{"key":"2024101707054353000_4.1.00127-2017.48","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008889"},{"key":"2024101707054353000_4.1.00127-2017.49","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13365"},{"key":"2024101707054353000_4.1.00127-2017.50","first-page":"633","article-title":"Ion channels as potential targets for the treatment of depression","volume":"11","author":"Lodge","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"2024101707054353000_4.1.00127-2017.51","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2013-1098"},{"key":"2024101707054353000_4.1.00127-2017.52","doi-asserted-by":"crossref","unstructured":"Can A , Dao DT , Arad M , et al. The mouse forced swim test. J Vis Exp 2012; e3638.","DOI":"10.3791\/3638-v"},{"key":"2024101707054353000_4.1.00127-2017.53","doi-asserted-by":"crossref","unstructured":"Yankelevitch-Yahav R , Franko M , Huly A , et al. The forced swim test as a model of depressive-like behavior. J Vis Exp 2015; e52587.","DOI":"10.3791\/52587"},{"key":"2024101707054353000_4.1.00127-2017.54","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/FBP.0000000000000266","article-title":"Investigation of antidepressant-like and anxiolytic-like actions and cognitive and motor side effects of four N-methyl-d-aspartate receptor antagonists in mice","volume":"28","author":"Refsgaard","year":"2017","journal-title":"Behav Pharmacol"},{"key":"2024101707054353000_4.1.00127-2017.55","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(99)00230-9"},{"key":"2024101707054353000_4.1.00127-2017.56","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.8.856"},{"key":"2024101707054353000_4.1.00127-2017.57","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12099"},{"key":"2024101707054353000_4.1.00127-2017.58","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.076372"},{"key":"2024101707054353000_4.1.00127-2017.59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709846"}],"updated-by":[{"DOI":"10.1183\/23120541.50127-2017","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000}}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00127-2017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T19:39:17Z","timestamp":1751485157000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00127-2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3,13]]},"published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1183\/23120541.00127-2017"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00127-2017","relation":{"correction":[{"id-type":"doi","id":"10.1183\/23120541.50127-2017","asserted-by":"object"}]},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}